Our study identifies YAP/TAZ as the primary signaling effectors downstream of LATS1/2 that drive luminal-basal plasticity in basal-like breast cancer, suggesting that abrogation of YAP/TAZ activity may be beneficial for the treatment of basal-like breast cancers. Here, LATS1 is linked to breast cancer.